News & Blogs

Commitment to Seniors Opposes Draft Regulations Under the Comprehensive Outbound Investment National Security (COINS) Act

Washington, D.C. – October 22, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the U.S. Treasury Department’s draft regulations under the Comprehensive Outbound Investment National Security (COINS) Act, which would expand restrictions on outbound investment in biopharmaceuticals. American seniors have the most to lose when government policies stand in the way of medical progress. Treasury’s proposed expansion of investment restrictions threatens to do exactly that. By preventing American companies from pursuing…

Learn More

Washington’s Proposed China Crackdown Could Backfire on American Patients

Several of the most exciting breakthroughs in cancer care are coming from China. New rules proposed by the Trump administration could make it harder for American patients to access those medicines. On October 22, the Treasury Department proposed expanding restrictions on American investment in Chinese companies to include biotechnology. The proposal aims to prevent American capital and expertise from helping China develop technologies that could threaten U.S. national security. That’s a legitimate concern. But there’s…

Learn More

Why Investment Protectionism Won’t Help American Biotech

The Trump administration just proposed new restrictions on American investment in Chinese biotechnology companies. Some industry leaders believe such measures could help American biotech startups attract more investment. Jacob Becraft, CEO of Massachusetts-based Strand Therapeutics, has warned that the growing flow of capital to Chinese drug developers is starving promising American technologies of funding. But capital follows opportunity, not government directives. Restricting investment in China won’t necessarily steer more capital toward American biotech. Investors barred…

Learn More

CVS’ split doesn’t fix its fundamental problem

CVS Health is one of the largest companies in the U.S. It serves the health care needs of hundreds of millions of Americans annually, has a hand in nearly every part of the drug supply chain, and has more than $400 billion in annual revenue. So when it announced last Wednesday that it will split into two entities, the news made waves. Here’s the thing: Much of the media coverage frames this move as CVS…

Learn More

Don’t Ban U.S. Biotech Companies From China

No one wants America to outcompete China than we do. But restricting our biotech industry is no way to achieve that. America has invented some of the world’s most groundbreaking medicines. China is trying to catch up, and our lead in medical innovation could slip. The good news is the rivalry to win the race for the cure for diseases means more medical innovation overall and better health for everyone. That’s why the Treasury Department’s…

Learn More

The COINS Act: Penny Wise, Patient Foolish

Washington has finally figured out that biotechnology is a national security issue. Welcome to the party. The Chinese government has understood this for years, investing aggressively in pharmaceutical research, advanced manufacturing, and the scientific infrastructure that will determine who develops tomorrow’s medicines. While Washington was busy congratulating itself on America’s historic leadership in biotechnology, Beijing was busy building the competition. Now comes the Comprehensive Outbound Investment National Security (COINS) Act. Enacted last December, the law…

Learn More

GLOBE: A World of Bad Ideas for American Patients

Washington has a new idea for lowering prescription drug costs: Let other countries decide what American medicines should cost. It’s an appealing political proposition, particularly when Americans are understandably frustrated by high drug prices. Unfortunately, what sounds like common sense on the campaign trail can turn into very bad medicine once it becomes government policy. The Centers for Medicare & Medicaid Services has finalized its GLOBE model, which would tie the prices of certain Medicare…

Learn More

Update on Foreign Freeloading on American Drug Innovation

The U.S. is the global leader of biomedical innovation, and other nations are not paying their fair share for America’s groundbreaking research and development. Other rich countries use government price controls to limit their spending on brand drugs. President Trump has urged these countries to end the freeloading and start investing. While the U.K. answered the call and agreed to pay more for US brand drugs, other nations, including France, Germany, and Japan, are doubling…

Learn More